18th Conference on Retroviruses and Opportunistic Infections (CROI), 27 February-–3 March 2011, Boston

1 April 2011. Related: Conference reports, Conference index, CROI 18 (Retrovirus) 2011.

This annual conference remains the most important large scientific HIV meeting and is notable for making web casts of oral presentations and lectures rapidly available. Abstracts are online in a searchable database, many of which also include the option to download the PDF poster.

We have plenty to report in this and subsequent issues of HTB, leading with the broad number of papers focusing on new drugs and biomedical interventions to reduce the risk of transmission.

http://www.retroconference.org

Reports in this issue include:

• New antiretrovirals: dolutegravir, entry inhibitor (BMS-663068) and tenofovir pro-drug (GS-7340)
• Immune-based treatment increases HIV-resistant CD4 cells in phase 1 study
• Antiretroviral prevention: oral PrEP, gels and treatment studies
• Further efficacy analyses from the iPrEx study
• Topical gels as PEP and PrEP in human and animal studies
• Maternal risk following short course HAART
• Pre-term delivery and HAART
• HAART more effective than AZT monotherapy in the Botswana PMTCT programme
• Lopinavir/r monotherapy for PMTCT
• No evidence of increased risk of MTCT with sequential pregnancies in UK and Ireland
• Recently infected women at the time of delivery have a higher rate of in-utero transmission in PEPI-Malawi
• Reduced CCL2 concentrations in cervicovaginal secretions from pregnant women
• First results from telaprevir in HIV/HCV coinfection
• HCV reinfection rates in HIV-positive gay men